Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BILR 355 + Ritonavir in Healthy Volunteers
NCT02253927Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2006
- Primary completion
- Aug 2006
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of BILR 355 in human immunodeficiency virus infection (HIV), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity, Maximum measured concentration of the analyte in plasma and 4 more. Started May 2006; status: completed.
02
Drugs
BILR 355
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02253927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253927.